Claims for Patent: 12,208,086

Summary for Patent: 12,208,086

Title:	Stable pharmaceutical compositions of bendamustine
Abstract:	Stable, injectable pharmaceutical compositions are provided, which are useful as ready-to-dilute (RTD) or ready-to-use (RTU) liquid injectable compositions comprising bendamustine or a pharmaceutically acceptable salt thereof, and which are suitable for intravenous administration. Preferably, solution formulations comprise (a) bendamustine, or pharmaceutically acceptable salts, solvates, or hydrates thereof, (b) at least one pharmaceutically acceptable non-aqueous solvent; (c) optionally, at least one pharmaceutically acceptable excipient, and (d) optionally, a pH adjuster, where the pharmaceutical composition is antioxidant-free, and formulated as a ready-to-dilute or ready-to-use liquid composition suitable for parenteral administration. The invention further relates to methods for manufacturing stable, antioxidant-free injectable solutions of bendamustine.
Inventor(s):	Harish Govindaraja Setty CHINNARI, Somashekhar BATTINI, Sumitra Ashokkumar PILLAI, Lourdu Chinnu Thippabattuni, BALASUBRAMANIAN Satheesh
Assignee:	Azurity Pharmaceuticals Inc
Application Number:	US18/502,396
Patent Claims:	1. A method of treating chronic lymphocytic leukemia or indolent B cell non-Hodgkin's lymphoma comprising administering to a subject in need thereof, a therapeutically effective amount of bendamustine in a liquid composition, said liquid composition consists of: a) about 25 mg/mL of bendamustine or a pharmaceutically acceptable salt thereof; b) a solvent mixture of polyethylene glycol and ethanol; c) monothioglycerol; and d) optionally, sodium hydroxide; wherein a level of total impurities in said liquid composition is not more than 5% w/w when stored at a temperature from about 2° C. to about 8° C. for 24 months as measured by HPLC, wherein the ethanol is about 2-25% w/w and the polyethylene glycol is about 75-98% w/w, respectively, in the solvent mixture of polyethylene glycol and ethanol. 2. The method according to claim 1, wherein the bendamustine or pharmaceutically acceptable salt thereof is bendamustine hydrochloride. 3. The method according to claim 1, wherein the polyethylene glycol is PEG-400. 4. The method according to claim 1, wherein the ethanol is about 2-5% w/w and the polyethylene glycol is about 90-98% w/w, respectively, in the solvent mixture of polyethylene glycol and ethanol. 5. The method according to claim 1, wherein the liquid composition has a pH ranging from 2.7 to 3.7. 6. The method according to claim 1, wherein a level of ethyl ester impurity in said liquid composition is not more than 0.5% w/w when stored at a temperature from about 2° C. to about 8° C. for 24 months as measured by HPLC. 7. The method according to claim 1, wherein the ethanol is 39.45 mg/mL in the solvent mixture of polyethylene glycol and ethanol.